PDF herunterladen
CC BY 4.0 · TH Open 2022; 06(02): e99-e106
DOI: 10.1055/a-1783-9744
Original Article

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study

Elisa Grifoni 
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Andrea Baroncelli
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Gabriele Pinto
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Eleonora Cosentino
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Irene Micheletti
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Ira Signorini
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Grazia Panigada
2   Internal Medicine, SS. Cosma and Damiano Hospital, Azienda USL Toscana Centro, Pescia, Italy
,
Giancarlo Landini
3   Internal Medicine, S. Maria Nuova Hospital, Azienda USL Toscana Centro, Florence, Italy
,
Luca Masotti
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints
Zoom Image

Abstract

Introduction Few data exist on the use of edoxaban in cancer-associated venous thromboembolism (VTE) outside of clinical trials. Aim of this study was to evaluate the characteristics and outcomes of these patients in a real world clinical setting.

Methods We retrospectively analyzed the characteristics of patients with cancer-associated VTE who were prescribed edoxaban. Follow-up at 3, 6, and 12 months was performed: VTE recurrences, bleedings, mortality, cancer progression and treatment, edoxaban interruption and its reason were assessed.

Results Fifty-four patients, 38 females (70.4%), mean age 71 ± 14 years, were enrolled. In 38 patients (70.4%), the episode of VTE was the first one, in 28 (51.8%) it was an isolated deep vein thrombosis (DVT), in 13 (24.1%) a pulmonary embolism (PE) associated with DVT, in 13 (24.1%) an isolated PE. Median time between cancer and VTE diagnosis was 6 (interquartile range [IQR] 2–47) months. Median time between VTE diagnosis and edoxaban prescription was 36 (IQR 7–117) days. At 3, 6, and 12 months the incidence of all-cause mortality was 16.6, 22.2, and 38.8%, that of VTE recurrence 1.8, 1.8, and 3.7%, and that of major bleeding 7.4, 9.2, and 12.9%, respectively. No bleeding was fatal. Of the 33 patients alive at 12 months, 32 (96.9%) were still on edoxaban therapy, in seven (21.2%) cancer was in progression.

Conclusion Our study, conducted on a real world population of patients with cancer-associated VTE, confirms the results of randomized controlled clinical trials, and supports the use of edoxaban as effective and safe treatment in this context.

Keywords

cancer - venous thromboembolism - bleeding - edoxaban - low molecular weight heparin

Supplementary Material



Publikationsverlauf

Eingereicht: 30. November 2021

Angenommen: 01. Februar 2022

Accepted Manuscript online:
01. März 2022

Artikel online veröffentlicht:
17. Mai 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany